Zoetis Inc. (NYSE: ZTS), formerly the animal health business unit of
Pfizer Inc., announced plans to expand its manufacturing facility in
Lincoln, Neb., to facilitate the production of high-quality, reliable
medicines for veterinarians, livestock producers and the animals under
their care. A world leader in animal health, Zoetis expects this
expansion to affirm its longstanding commitment to being a world-class
manufacturer of animal health products as well as to continue to be an
employer of choice in Lincoln.
The plan calls for a 19,000 square-foot, three-story expansion of the
existing production facility to accommodate the transfer of products
from a third-party manufacturer to Lincoln. Early stages of planning and
construction have begun and groundbreaking is expected to occur later
this summer, initiating the start of the full construction phase. Zoetis
expects to complete construction in 2014.
This expansion will help ensure a reliable, consistent supply of quality
medicines for animals. Today, Zoetis produces some of its flagship
pharmaceutical products and vaccines at the Lincoln plant, including Bovi-Shield
Gold® and RespiSure
One® for livestock and Rimadyl®
for dogs. The site is one of the largest internal manufacturing
operations within Zoetis, employing more than 500 people today; the
facility expansion could create as many as 30 new positions at peak
production time.
“Zoetis is excited about the opportunity to expand its manufacturing
footprint in Lincoln and to leverage the expertise in high-quality
manufacturing that our colleagues have demonstrated in Lincoln for
decades,” said Michael Morgan, site leader in Lincoln.
Zoetis and its predecessors have long held a presence in the Lincoln
area. In the early 20th century, drug firms and distributors
such as Norden Laboratories established facilities in Nebraska that
evolved over time. Since then, more recent incarnations of these animal
health companies, including the Zoetis facility, have continued to serve
as an important part of the Lincoln community. The Lincoln facility is a
key site in Zoetis’ global manufacturing network and one of the largest
suppliers of Zoetis’ animal health products for the world. It has been
in operation at its current location since 1961, producing 1,200
finished goods for more than 100 markets annually.
“This expansion shows our continuing commitment to the Lincoln
community, a community that we have been a part of for several decades.
We are proud of our new name, Zoetis, and look forward to continuing to
produce great quality medicines and vaccines for our customers,” said
Morgan.
About Zoetis
Zoetis
(zō-EH-tis) is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on a 60-year
history as the animal health business of Pfizer, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and medicines,
with a focus on both farm and companion animals. The company generated
annual revenues of $4.3 billion in 2012. It has more than 9,300
employees worldwide and a local presence in approximately 70 countries,
including 29 manufacturing facilities in 11 countries. Its products
serve veterinarians, livestock producers and people who raise and care
for farm and companion animals in 120 countries. For more information on
the company, visit www.zoetis.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, which reflect
Zoetis’ current views with respect to business plans or prospects,
future operating or financial performance, and other future events.
These statements are not guarantees of future performance.
Forward-looking statements are subject to risks and uncertainties. If
one or more of these risks or uncertainties materialize, or if
management's underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a
forward-looking statement. Forward-looking statements speak only as of
the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. A
further list and description of risks, uncertainties and other matters
can be found in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2012, including in the sections thereof captioned
“Forward-Looking Information and Factors That May Affect Future Results”
and “Item 1A. Risk Factors”, and in our reports on Form 8-K. These
filings and subsequent filings are available online at www.sec.gov
or on request from Zoetis.
Internet Posting of Information
We routinely post information that may be important to investors in
the 'Investors' section of our web site at www.zoetis.com,
on our Facebook page at http://www.facebook.com/zoetis
and on Twitter @zoetis. We encourage investors and potential investors
to consult our web site regularly and to follow us on Facebook and
Twitter for important information about us.
Copyright Business Wire 2013